Why is Balaxi Pharma falling/rising?

As of 13-Jun, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 51.99, which reflects a decrease of 0.94 or 1.78%. The stock has underperformed its sector by 1.26% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the delivery volume has significantly decreased by 56.72% compared to the 5-day average, indicating falling investor participation. Over the past year, the stock has generated a return of -58.11%, while its profits have also fallen by 31.3%. Despite having strong long-term fundamentals, such as an average Return on Equity (ROE) of 30.97% and healthy growth in net sales, the stock's recent performance has been negatively impacted by flat quarterly results and below-par performance in both the long and near term.
In the broader market context, Balaxi Pharmaceuticals' short-term return of +0.08% over the past week contrasts with the Sensex, which has declined by 1.14%. This indicates that while the stock has shown slight resilience in the short term, its overall performance remains weak, particularly when compared to the benchmark's positive return of 4.54% year-to-date. The stock's long-term underperformance, with a decline of 28.10% year-to-date and a significant drop over the past year, highlights the challenges it faces in regaining investor confidence amidst a backdrop of broader market stability.